High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms INCREASE
- Sponsors Betta Pharmaceuticals Co Ltd
- 27 Jul 2017 Status changed from active, no longer recruiting to recruiting.
- 09 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2018.
- 09 Feb 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2017.